Relmada Therapeutics, Inc.

RLMD

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$4.47

−$0.16 · -3.46%

Aug 24, 10:55 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

46/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Neutral

Sentiment

Bullish

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Sergio Traversa
Listed since: Jun 20, 2014
Employees: 17

Market position

Day range

Current $4.47

$4.375$4.64

52-week range

Current $4.47

$0.595$8.00

Open: $4.64
Previous close: $4.63
Volume: 159.9K; 0.1× average
Average volume: 1.57M; Average daily volume
Market cap: 468.86M USD
Beta: 0.49; Market reference 1
50-day average: $5.7274; -21.95% below average
200-day average: $5.4172; -17.49% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 187.19M USD
P/E (TTM): -4.86×
P/B (TTM): 2.43×
P/S (TTM): 0×
EV / EBITDA: -3.26×
Earnings yield: -30.09%
Free cash flow yield: -24.01%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -66.33%
Return on assets: -61.05%
Return on invested capital: -67.49%

Financial health

Debt / equity: 0×
Current ratio: 14.62×

Financial statements

Income trends

Operating income

−59.1M USD+29.55%

Net income

−57.39M USD+28.25%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	744.56K USD	46.18M USD	54.81M USD	113.32M USD	90.62M USD
Selling, general, and administrative	311.9K USD	37.72M USD	48.9M USD	47.93M USD	35.08M USD
Operating expenses	59.1M USD	83.89M USD	103.7M USD	161.25M USD	125.7M USD
Interest income	1.4M USD	3.53M USD	5.15M USD	2.66M USD	1.2M USD
Depreciation and amortization	—	—	103.7M USD	2K USD	1.26K USD
Operating income	−59.1M USD	−83.89M USD	−103.7M USD	−161.25M USD	−125.7M USD
Net income	−57.39M USD	−79.98M USD	−98.79M USD	−157.04M USD	−125.75M USD